ABSTRACT. We report the comparison of noninvasive methods to estimate whole body leucine oxidation in patients who have maple syrup urine disease. We used both an i.v. and an oral bolus of ~-[l-~~Cjleucine and quantitated 13C02 in expired air. Both methods differentiated patients with maple syrup urine disease from heterozygous and control subjects. Eight patients, whose disease differed in clinical severity, were selected for study and had a range of impaired values for whole body leucine oxidation. Six h after an i.v. bolus dose of L-[1-13Cj-L-leucine, 13C02 recoveries ranged from 0.8 to 19.7%. Three of the eight patients had significant increases in 13C02 production after supraphysiologic thiamine therapy. After the oral dose of L-[I13Cjleucine, homozygous affected children produced less 13C02 than normal, age-matched, childhood controls. In addition, the oxidation of orally administered ~-[ l -'~C j leucine was reduced significantly in adult heterozygotes compared with adult controls. The proportion of whole body leucine oxidation by affected children was comparatively greater than that by their cultured cells, but cellular oxidation correlated significantly with whole body oxidation of leucine among affected patients. We conclude that these simplified analyses of whole body leucine oxidation define the degree of impaired branched-chain cr-ketoacid dehydrogenase activity in patients with differing types of maple syrup urine disease and distinguish the subpopulation who might benefit from thiamine supplementation. (Pediatr Res 33: 445-451, 1993) and their respective a-ketoacids (a-ketoisocaproate, a-ketoisovalerate, and a-keto-0-methylvalerate) (1-3), which are believed to be toxic to the CNS. The prognosis for newborn infants who have MSUD is directly linked to the degree of impaired BCKD enzyme activity and such confounding variables as irreversible damage conferred on the CNS before a BCAA-restricted diet is implemented (4) . The BCKD enzyme complex is made up of four protein subunits (Ela, E10, E2, and E3), a BCKD-specific kinase, and phosphatase. BCKD is situated in the matrix on the inner mitochondria1 membrane (5, 6) . The E2 subunit forms the core of the complex to which the El and E3 are attached (7) . Thiamine pyrophosphate is a cofactor that, in the presence of Mgf+, forms the binding site for the branched-chain ketoacid substrate on the E l a subunit. The enzyme activity is regulated by a specific kinase and a phosphatase; thus, BCKD activity varies in different tissues. Under normal dietary conditions, most (79%) of the complex in liver is in the active state, whereas between 30 and 40% of the total complex in cultured dermal fibroblasts is in the active state (8) .
Sensitivity to dietary BCAA is reduced in some MSUD patients after they have ingested pharmacologic doses of thiamine (5 mg. kg-'. d-') for a minimum of 3 wk (9-1 1). Normal leucine tolerance has never returned, however, and the degree of response to thiamine is difficult to assess. Although a mechanism for the response to thiamine has not been confirmed, several hypotheses have been proposed including stabilization of the enzyme complex (3, 12, 13) .
After MSUD is detected by newborn screening techniques, the diagnosis, nutritional management, and prognosis of the patients would be simplified if a clinically useful method were available to estimate BCAA oxidation in vivo. WBLO measurements would determine overall BCKD activity in a population of patients with a heterogeneous continuum of impaired function and include the contribution by differentiated tissues such as liver, muscle, and kidney. These tissues represent most of the total BCKD activity of the organism. Sequential measurements before and during thiamine therapy might also identify the patients in whom pharmacologic doses of thiamine will produce a positive response. We report the development of two breath tests that quantitate the oxidation to I3CO2 of a single bolus of L-[l-'3C]leucine administered either intravenously or orally. These single bolus methods bypass the relatively invasive techniques of constant infusion and multiple blood testing required of steady state techniques. We compared WBLO among three genotypes: homozygous affected, heterozygotes, and normal controls. We correlated in vivo WBLO with in vitro assays of L-[I-14C]leucine decarboxylation by peripheral and cultured cells from the same heterogenous group of patients with MSUD.
MATERIALS AND METHODS
Study population. Eight children 5 to 9 y of age, previously unreported with MSUD (homozygous affected), were studied, as were six of their parents (heterozygote) and seven normal adults (control). Before the study began, the MSUD patients had consumed diets restricted in BCAA and had received at least 180% of the recommended dietary allowance for thiamine. Individual dietary records were maintained for all patients. Table 1 gives a summary of their clinical status at the time of study, in addition to their calculated leucine intakes and ranges of plasma leucine concentrations. All subjects were studied after an overnight fast. Informed consent was obtained from each subject and his or her parents after a thorough explanation of the purpose of the study, the diet regimen, and the protocol for the kinetic measurements. Table 2 using the Schofield equations for BMR (15) and the Weir equation (1 6) to obtain C 0 2 production based on an energy expenditure of 1.4 times BMR and a fasting RQ of 0.80. The standard error of the estimates of C02 production values for an individual are given by the Schofield equations for BMR: the range is from 6 to 10% depending upon age. The C 0 2 production values were combined with the isotopic enrichment data to obtain percent dose recovered at each time point and integrated by trapezoidal methods to obtain the cumulative percent dose recovered. With the quantities of substrate used, the analytical sensitivity of dose recovered was 0.003%. Enzyme assays. Granulocyte-free, mononuclear white blood cells were prepared from 8 to 10 mL of heparinized blood in a Ficoll density gradient using modifications of a previously described method (17) . Lymphoblasts were transformed from peripheral monocytes using Epstein-Ban viral transformation (1 8).
Fibroblasts were cultured from biopsied skin in Dulbecco's and Vogt's media using standard methods (19) . 1-14C-leucine decarboxylation to I4CO2 was assayed in the mononuclear cell fraction or monolayer of cells isolated or cultured from the patient and normalized for protein content. To minimize day-to-day assay variation, results in patients' cells were compared with two control cells prepared and assayed under identical conditions on the same day. Results were expressed as percentage of control. Statistical analyses. The t test was used for analyses among groups of patients and heterozygous and normal control subjects. Linear regression analyses were used to correlate WBLO and cellular oxidation by individuals (20) .
RESULTS
The patients with MSUD and their clinical histories are summarized in Table 1 . All patients were between 5 and 9 y of age. They were chosen to represent a spectrum of phenotypic expression and to estimate the continuum of expected impairment. MR and AR are siblings and are on no formal BCAA restriction because symptoms occur only with excessive protein intake. Leucine intake remained constant for each volunteer during all studies conducted at the Clinical Research Facility.
Intravenous breath test. When this i.v. bolus method was compared among the eight homozygous affected children, six heterozygous parents, and seven normal adult controls, the pattern of leucine oxidation among the three genotypes was consistent with that seen in Figure 1 , and initial rates could be compared with total leucine oxidation (Fig. 2) . The range of I3CO2 recovery was broad among patients at both 10 min and 6.0 h. The percent dose oxidized in 10 min ranged from 0 to 0.04% with a mean of 0.01 %, and at 6 h. from 0.0 to 8.1% with a mean of 3.9%. These values were clearly different from those of either the homozygous normal controls ( p < 0.001) or their heterozygous parents ( p < 0.001).
The ranges of leucine oxidation by adult heterozygotes and homozygous normal adult controls overlapped completely. At 10 min, the mean percent dose recovered was 0.1 % and 0.2%, and at 6.0 h, was 19.4 and 20.1 % for heterozygotes and controls, respectively (Fig. 2) .
WBLO values of the patients with MSUD (before and during thiamine treatment) were expressed as a percentage of control and correlated to plasma leucine concentration and cellular (5 mg/kg), expired I3CO2 was quantitated by gas-isotoperatio mass spectrometry at the times indicated. I3CO2 data are from duplicate observations and are expressed as percent dose recovered: a homozygous affected patient (RD = W), a heterozygote parent (MM = 0), and a homozygous normal control (RF = 0) were studied on the same day. leucine oxidation values (Table 3) . WBLO values of three patients increased during thiamine administration (LF, AJ, and NL). Thiamine therapy also decreased plasma leucine concentrations when the dietary leucine intakes of the subjects were identical. WBLO and plasma leucine concentrations in the other five patients (RD, JS, MR, BH, and AR; Table 3 ) and all controls (not shown) showed no response to thiamine (Table 3 ). This correlation of WBLO to plasma leucine concentrations was expected, because changes in leucine pool size should have an inverse effect on leucine oxidation rates. One patient (BH) did not respond to thiamine therapy and oxidized 6.2% of leucine to C 0 2 on his basal study but oxidized 0% while taking thiamine.
Because it was necessary to restrict his dietary leucine intake to 2 1 mg . kg-' . d-' (Table 1) formed lymphoblasts, and cultured fibroblasts oxidized leucine at only 0.9 to 2% of controls (Table 3) (Table 3) . On the basis of simple regression analyses, WBLO correlated best with lymphoblast BCKD activity (r = 0.885, p = 0.008), second best with fresh peripheral 1ymphoc.ytes ( r = 0.80 1; p = 0.03), and least with cultured dermal fibroblasts (r = 0.697, p = 0.08). The addition of thiamine (100 mg/L) to the culture medium did not affect BCKD whether or not patients were "thiamine responsive" (data not shown). This finding further supported the need for an in vivo method with which to comvare leucine oxidation in patients both off and on high-dose thbmine therapy.
The percentage of overall leucine oxidation was relatively high in the patients compared with the percentage in their cultured cells (Table 3 ). The range in percentage of control for WBLO by all eight patients on thiamine therapy was 0.0 to 40.0%, whereas their lymphoblast oxidation values ranged from 2.0 to 24.0% of control values. Individual patient WBLO values were greater than his or her cellular oxidation values, suggesting the presence of more residual leucine decarboxylation activity in differentiated organs, such as liver, muscle, and kidney, than in their individual cellular preparations.
Oral breath test. The percent dose oxidized over the 6 h differentiated the homozygous affected patient (RD), her heterozygous mother (MM), and a normal adult control (RF) (Fig.  3) . By comparing leucine oxidation rates after i.v. administration with those after oral administration, several differences in the time courses among the genotypes were apparent (Fig. 1 versus  Fig. 3 ). This affected child was discriminated on the basis of early time points (10 min after i.v. administration), whereas I3CO2 appearance in breath after oral administration was influenced by intestinal absorption with a greater variation in the time required to reach peak values. These differences were consistent within genotypes and suggested a secondary effect on intestinal leucine transport. After oral leucine administration, values for the normal control showed prompt absorption and oxidation of ingested leucine, whereas the heterozygous parent showed a delayed and broadened peak of oxidation (Fig. 3) . This time course appeared to exaggerate the results by the i.v. methods (Fig. I) . The homozygous affected patients produced very little 13C02 before 240 448 ELSAS ET AL Table 3 . Comparison of WBLO a n d cellular oxidation in eight homozygous deficient MSUD patients before (-) a n d during (+) min, but label appeared in breath after this time. This delayed appearance of I3CO2 in affected patients may have resulted from utilization of leucine by intestinal flora. The affected child was easily differentiated from age-matched controls at 60 rnin after substrate ingestion (Figs. 4 and 5) .
When breath test curves for the homozygous affected patients and age-matched controls were compared, the patients excreted less 13C02 between 60 and 90 min after L-[l-'3C]leucine ingestion than controls (Figs. 4 and 5) . Because of increased I3CO2 production between 240 and 360 rnin by affected patients, these latter time points were less discriminating with oral methods (Figs. 4 and 5) . Because of the delay in the onset of L -[~-'~C ] leucine oxidation in homozygous affected patients, the interval at which 13C02 measurements were most discriminating was between 60 and 90 rnin rather than either the 10-or 30-min time points used in the i.v. protocol.
Statistical evaluation of the time points at 60, 90, and 240 min is shown in Figure 5 in which the cumulative percent doses recovered as I3CO2 in breath from the six patients and seven age- matched controls were compared. There were no overlapping values at any of these time points, and clinically affected children, including five "variant" patients, were statistically different from unaffected control children (p < 0.001). These integral values showed that homozygous affected children had a mean WBLO value of 3.8 + 3.1% compared with 12.3 k 2.3% for controls ( p < 0.001). In addition, the percent dose excreted as 13C02 at 60 or 90 rnin after leucine was administered could be used as a discriminant function for impaired BCKD.
One unexpected finding was that the oral breath test differentiated adult obligate heterozygotes from homozygous normal controls (Table 4 ). These differences were most striking in the cumulative percent dose values at the 60-and 90-min time points of analysis (p < 0.001 by t test). (22, 23) found little or no enrichment of breath 13C02 after primed constant infusions of leucine. Although WBLO was not compared with cellular leucine oxidation in either study, different mutations of genes for the BCKD and different degrees of impaired enzyme functions were probably responsible for these differences in WBLO. Previous studies of leucine turnover kinetics have used a protocol requiring a primed-constant infusion of leucine as well as a second isotopically labeled amino acid, multiple blood and breath samples from indwelling catheters, and a second day of NaHI3CO3 retention analysis for normalization of 13C02 recovery. Understandably (22) (23) (24) (25) , it has been difficult to recruit children as controls or to repeat studies in the same patient. We present simpler methods to measure L-[l-13C]-leucine oxidation to 13C02 using a single bolus of leucine (5 mg/kg) administered either by injection or ingestion without blood sampling. This simplified approach, using only measurement of I3CO2 in expired air, does not provide detailed kinetic analysis of leucine metabolism or protein turnover rates. In addition, leucine pools will affect oxidation rates; this is an anticipated and desirable relationship for studies in which the diagnosis and management of patients with impaired leucine oxidation are to be studied. (Table 3) . Third, of the three genotypes studied using either i.v. or oral bolus techniques, patients with clinically impaired BCKD were clearly different from obligate heterozygotes or controls who were homozygous for the normal alleles. Fourth, unaffected heterozygotes with normal plasma leucine concentrations had less leucine oxidation than controls (Table 3) , supporting the contention that these I3CO2 breath tests primarily measure leucine oxidation through the BCKD pathway. It should be realized, however, that the six obligate heterozygous individuals studied were parents of patients with severe BCKD impairment. We are presently attempting to determine whether heterozygous individuals who have less severe mutant alleles can be detected by these oral leucine oxidation studies. Thiamine responsiveness in patients with MSUD can be estimated by a variety of methods, but all are complex or difficult to standardize (3, 9, (10) (11) (12) (13) (26) (27) (28) (29) . Several theories were generated from studies of cellular fractions from patients (3, 30, 3 I), but testing these hypotheses in vivo necessitates that patients undergo weeks of hospitalization in a clinical research unit to enable standard balance studies (13) . Using the methods described in the present study, a clinical response to as few as 3 wk of thiamine therapy (5 mg/kg) was confirmed or denied by increased oxidation of ~-[l-~~C]leucine in a single day (Table 3) . While two patients (LF and AJ) were receiving supraphysiologic doses of thiamine, their WBLO levels were readily measurable at 17.0 and 6.0%, respectively, of controls. When thiamine was removed from their diets, which were otherwise constant in BCAA content, these patients became ataxic and developed high plasma leucine concentrations and their WBLO levels dropped to zero. Thiamine responsiveness was not directly related to residual enzyme activity, as seen in siblings AR and MR, who had an "intermittent" form of MSUD with relatively high residual BCKD but demonstrated no increase in WBLO on thiamine therapy. Their results also exemplified the reproducibility of our methodology. The results of leucine oxidation studies (I mo apart) were similar: 40.0 and 34.0% of control for MR and 38.0 and 39.1 % of control for AR before and during thiamine administration, respectively (Table 3) . Although these parameters do not explain the mechanism by which patients respond to thiamine, they do enable a more precise clinical definition of the type of MSUD in a given patient and his or her thiamine responsiveness.
Of the two methods of bolus administration (i.v. and oral), the 450 ELSAS oral test involves only the ingestion of a few teaspoons of a tasteless solution and the collection of a few breath samples at timed intervals and would enable field studies in children. The oral breath test reflected a number of variables in addition to WBLO, such as gastric emptying, enteral absorption, and the possibility of leucine utilization by intestinal flora. These responses were reflected in the control subjects by the slower rise and broader peak of maximum oxidation after oral administration of leucine compared with i.v. injection. Of particular interest was the late peak of I3CO2 that appeared in MSUD patients. This peak probably reflected the capacity of intestinal flora to oxidize L-[l-13C]leucine to 13C02 rather than endogenous oxidation. This late peak was not present in the control children or in the patients when they received the leucine by i.v. administration. Despite these differences, the percent dose oxidized at 60, 90, and 240 min after leucine ingestion clearly differentiated the heterogeneous group of MSUD patients from childhood controls (Fig.  5 ). Of considerable interest was the fact that the mean value for oxidation of oral leucine by heterozygotes was significantly different from that of the adult homozygous normal controls ( Table  4 ). The fasting plasma leucine concentrations in all heterozygous and homozygous normal controls were in the normal biologic range. The heterozygous individual, AR, was the parent of NL, and parents of LF, AF, FS, RD, and BH were the other five heterozygous persons studied. Parents of the "intermediate" MSUD patients, MR and AR, were not available for study. Although leucine intake could affect leucine transport by the jejunum (24), preliminary diet histories do not indicate that parents and controls had different protein or leucine intakes. Thus, this finding probably reflects real differences in endogenous hepatic oxidation of leucine by heterozygotes for impaired BCKD and supports the contention that these non-steady state leucine oxidation methods measure the BCKD pathway. We have thus established that leucine breath tests of WBLO have a relatively broad range of applicability and can be used to identify clinically significant BCKD deficiencies. These noninvasive, simple methods will enable an increase in epidemiologic assessments of the heterogeneous group of patients with impaired BCKD and identification of thiamine-responsive patients, and perhaps the oral breath test will enable the identification of heterozygotes. These tests can also be used in conjunction with molecular advances in understanding and treating MSUD.
At the molecular level, the cDNA for four of the enzymes producing the multienzyme BCKD complex have been cloned (32) (33) (34) (35) . The E2 cDNA has produced stably transfected fibroblasts from an E2-MSUD patient and could be placed in retroviral vectors suitable for hepatic or muscle cell transfection and autologous transplantation (36) . Measurement of WBLO will be useful in recurrent evaluation of the efficiency and stability of gene transfer into individual patients with MSUD when this form of therapy becomes available (37) .
